| (Values in U.S. Thousands) | Feb, 2026 | Feb, 2026 | Feb, 2026 | Feb, 2026 | Feb, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Kyowa Hakko Kogyo (KYKOF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kyowa Hakko Kirin Co Ltd is engages in the manufacture and marketing of pharmaceuticals and bio-chemicals in the areas of cancer, allergies, renal anemia, & hypertension. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test and develops technologies for antibody drug creation, among others. The Biochemical segment manufactures and sells medical and industrial materials, mainly amino and nucleic acids, and healthcare products. The Company operates its business in in Asia, Europe, and the United States.